News & Press Releases
Filter by:
Strategic Allies: How Communications Teams Can Drive Law Firm Growth by Supporting Key Client Account Teams
August 1, 2025
Mintz’s Chief Marketing & Business Development Officer Chris Newman was quoted in The Legal Intelligencer in an article about how communications professionals can boost law firm growth by supporting key client account efforts and contributing their insights to important firm relationships.
Intelligize referenced a recent article by Mintz Member Jacob Hupart in its coverage of the ongoing court challenges to the Securities and Exchange Commission’s climate disclosure rule. Jacob’s piece examines the Eighth Circuit’s decision to hold litigation over the rule “in abeyance.”
Law360 quoted Health Law Practice Chair and Health Care Enforcement Defense Practice Co-chair Karen Lovitch in an article about a Ninth Circuit opinion affirming that a California man's fraud conviction provides insights for the owners of medical testing laboratories regarding what sales tactics are permitted under a 2018 kickbacks law.
Law360 published an article written by Privacy & Cybersecurity Practice Co-Chair Cynthia Larose and Associate Bertie Magit about the fiscal year 2026 New York State executive budget. In the article, the attorneys discuss five issues related to the consumer protection compliance measures signed into law by New York Governor Kathy Hochul.
SEC Accused of Relying on Court to Nix Climate Rule
July 25, 2025
Lexology PRO quoted Mintz Member Jacob Hupart in an article about a status report the SEC filed, asking the Eight Circuit Court of Appeals to decide whether its proposed climate disclosure rule is legal. The SEC declined to confirm whether it plans to implement the regulation.
Is Biopharma M&A In a Holding Pattern or a ‘New Normal’
July 23, 2025
Life Sciences International Chair Cheryl Reicin recently joined the Scrip M&A Podcast to share insights on the evolving landscape of biopharmaceutical mergers and acquisitions. In the episode, Cheryl highlights an uptick in pre-M&A activity, as major pharmaceutical companies increasingly leverage license and option agreements to strengthen their pipelines and product portfolios while positioning themselves for potential future acquisitions.
